HCRN: PH2 - Open label, Pacritinib in R/R T-Cell Lymphomas

Purpose of this Study

We are doing this study to find out if an experimental drug called pacritinib (the study drug) is a safe and effective treatment for people with T-cell lymphoproliferative cancers. We want to know how well it works for patients diagnosed with peripheral T-cell lymphoma (PTCL) or cutaneous T-cell lymphoma (CTCL).

Who Can Participate?

Eligibility

Adults ages 18+ diagnosed with PTCL or CTCL that has relapsed or failed to respond to treatment. For more information about who can join this study, please contact the study team at terri.lucas@duke.edu.

What is Involved?

Description

If you choose to join this study, you will go through a screening period to find out if you are eligible. During this screening period, you will:
  • Have a physical exam
  • Have a heart scan (ECG, Echo)
  • Have blood draws
  • Have bone marrow samples taken (PTCL patients only)
  • Have a tissue biopsy (lymph node)
  • Have a skin biopsy (CTCL patients only)
  • Have imaging (PET/CT)
If you are eligible to continue in the study after screening, you will begin taking the study drug. The study drug is a capsule that you take by mouth, and you will take the study drug every day at the same time. You will take the study drug for as long as the study doctor believes you are receiving a benefit.

Study Details

Full Title

Phase 2, open label, multicenter study of pacritinib in relapsed/refractory T-cell
lymphoproliferative neoplasms

Principal Investigator

Jie
Wang

Protocol Number

PRO00113497

NCT ID

NCT04858256

Phase

II

Enrollment Status

Open to Enrollment
ClinicalTrials.gov